Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.40 |
| ▸ | UGCG | Q16739 | 3/20 | 0.40 |
| ▸ | WNT1 | P04628 | 5/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1572184 | 0.93 | GSK3B (0.48) | GSK3BUGCGKCNH2CHRM5CHRNA3 | |
| Hydrochloric Acid SCHEMBL1572777 | 0.92 | GSK3B (0.47) | GSK3BUGCGKCNH2CHRM5CHRNA3 | |
| SCHEMBL14390881 | 0.80 | GSK3B (0.55) | GSK3BDYRK1AWNT1 | |
| SCHEMBL5043498 | 0.80 | GSK3B (0.53) | GSK3BDYRK1AWNT1KCNH2 | |
| SCHEMBL1176422 | 0.80 | GSK3B (0.53) | GSK3BDYRK1AWNT1KCNH2 | |
| SCHEMBL1572799 | 0.79 | GSK3B (0.59) | GSK3BDYRK1AWNT1JAK2KCNH2 | |
| SCHEMBL1970694 | 0.79 | CHRNA7 (0.62) | GSK3BDYRK1AWNT1KCNH2HTR3A | |
| SCHEMBL1963811 | 0.79 | CHRNA7 (0.62) | GSK3BDYRK1AWNT1KCNH2HTR3A | |
| SCHEMBL1966154 | 0.79 | CHRNA7 (0.62) | GSK3BDYRK1AWNT1KCNH2HTR3A | |
| SCHEMBL1572527 | 0.79 | PRKAB2 (0.46) | GSK3BDYRK1AUGCGJAK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745046-B1 | 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZIOSOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2011-04-13 | — | — | EP | claimed |
| US-7632831-B2 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-12-15 | — | — | US | claimed |
| EP-1745046-A2 | 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZIOSOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2007-01-24 | — | — | EP | claimed |
| US-20050272735-A1 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-12-08 | — | — | US | claimed |
| WO-2005111038-A2 | 1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | claimed |
| EP-1745046-B1 | 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZIOSOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20090325939-A1 | 1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | XIE WENGE | 2009-12-31 | — | — | US | disclosed |
| US-20090325939-A1 | 1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | XIE WENGE | 2009-12-31 | — | — | US | disclosed |
| US-7632831-B2 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632831-B2 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632831-B2 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1745046-A2 | 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZIOSOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050272735-A1 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-12-08 | — | — | US | disclosed |
| WO-2005111038-A2 | 1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325939-A1 | 1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA1, CHRNA5 | GSK3B 1110/4885DYRK1A 2107/4885UGCG 3836/4885 |
| US-20050272735-A1 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | CHRNA7, CHRNA1, CHRNA5 | GSK3B 1110/4885DYRK1A 2107/4885UGCG 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.